Shorter time to initiation of biologic therapy in the setting of a hidradenitis suppurativa specialty clinic

Hidradenitis suppurativa (HS) is a chronic condition with a significant psychological and physical burden but a paucity of effective treatments. Early intervention with adalimumab improves disease outcomes. Two previous studies in Denmark and Northern Ireland have identified a time of 8.2 and 2.9 years, respectively, from first HS systemic/dermatology consultation to commencing a biologic. We aimed to evaluate the time from disease onset and from first specialty HS clinic review to the initiation of biologic therapy. We retrospectively reviewed 34 patients on biologic treatment for HS. The mean diagnostic delay was 12.4 years. The mean time from disease onset to biologic initiation was 14.8 years. Prior to a biologic, patients received a median of 3.3 treatments from the specialty HS clinic. The median time to biologic from first presentation at the specialty HS clinic was 1 year. This is shorter than the therapeutic delay reported in dermatology clinics in Denmark and Northern Ireland, providing evidence on the importance of specialized HS treatment. However, to make an impact with specialized HS care and earlier biologic initiation, diagnostic delay needs to be reduced. Early intervention with adalimumab in hidradenitis suppurativa (HS) improves disease outcomes. Previous studies in Denmark and Northern Ireland have reported a delay from systemic to biologic treatment of 8.2 years and 2.9 years, respectively. In this retrospective review of 34 patients attending a specialty HS clinic, there was a shorter time to biologic treatment of just 1 year. This shorter therapeutic delay provides evidence on the importance of specialized HS care.